Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelitolimod + Radiation in Untreated Low-grade B-cell Lymphoma
NCT02266147Phase 2Terminated
- Sponsor
- Dynavax Technologies
- Start
- Oct 2014
- Primary completion
- Apr 2017
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nelitolimod in B cell lymphoma, sponsored by Dynavax Technologies. Primary endpoints: Dose-limiting Toxicities at Day 36, Injection-site Reactions at Day 36 and 2 more. Started Oct 2014; status: terminated.
02
Drugs
nelitolimod
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT02266147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266147.